Advanced searches left 3/3

Lvad - DOAJ

Summarized by Plex Scholar
Last Updated: 02 August 2022

* If you want to update the article please login/register

Design and execution of a verification, validation, and uncertainty quantification plan for a numerical model of left ventricular flow after LVAD implantation.

BACKGROUNDING Left ventricular assist devices are implantable pumps that serve as a life support therapy for patients with severe heart disease. Particularly, the LVAD's flow restriction in the left ventricle may lead to thrombus formation. Methods The simulation was conducted by the SDSU cardiac simulator, a bench mock-up of the cardiovascular device that allows for simulating multiple operating conditions for the heart-LVAD device. Alya solves the Navier-Stokes equation by an Arbitrary Lagrangian-Eulerian formulation in a deformable ventricle that includes pressure-driven valves, a 0D Windkessel simulation for the arterial output, and a LVAD boundary condition simulated by a dynamic pressure-flow performance curve. An uncertainty quantification of the inputs using six validation experiments that include extreme operating conditions; a risk analysis and the associated credibility objectives; and a testing phase to ensure correctness in the numerical solution process; and a monitoring stage to determine the impact of the inputs on the four quantities of concern. Numeric code verification results Numerical code verification tests ensured the solution procedure's correctness, while numerical calculation verification showed a grid convergence index of 95% 3. 3%. The complete Sobol indices obtained during the test QoIs showed that the ejection fraction, the heart rate, and the pump performance curve coefficients were the most useful inputs for the analysis. The Minkowski norm is used as a validation metric for uncertainty quantification. Comparing to the extreme cases, it shows that the midpoint cases have more accurate results.

Source link: https://doi.org/10.1371/journal.pcbi.1010141


Hemostasis Disturbances in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients—Rationale and Study Design

Patients with end-stage heart failure patients are a treatment option for left ventricular assist devices. We intend to evaluate the hemostasis system at four different time points, i. e. , before LVAD implantation, 3u20134 months after LVAD implantation, 6u201312 months after implantation, and at the end of the study.

Source link: https://doi.org/10.3390/jcm11133712


A Prospective Observational Study on Multiplate®-, ROTEM®- and Thrombin Generation Examinations Before and Early After Implantation of a Left Ventricular Assist Device (LVAD)

After left ventricular assist device implantation, heart failure patients are commonly on coagulation-active drugs before LVAD implantation and perioperative bleeding is a common complication. paraphrasedoutput:MethodsWe prospectively enrolled 25 patients with terminal heart disease in LVAD implantation and the early postoperative time course of these tests is not well established. We investigated whether preoperative TRAP-, ASPI-, ADP-, and ROTEM values are related to estimated blood loss during the first 21 days after LVAD implantation, comparing the baseline values of these measurements between patients with bleeding disorders to those without.

Source link: https://doi.org/10.3389/fmed.2022.760816


MicroRNA Expression in Myocardial Tissue and Plasma of Patients with End-Stage Heart Failure during LVAD Support: Comparison of Continuous and Pulsatile Devices.

In patients with end-stage heart failure, Pulsatile flow left ventricular assist devices are being replaced by continuous flow LVADs. Our results show a change in time pattern post-LVAD, with MiR-146a, miR-221 and miR-221. However, miR expression levels don't appear to vary between pf- and cf-LVAD, meaning that most cardiac changes or clinical outcomes specific to each device do not appear to be significantly different between pf- and cf-LVAD.

Source link: https://doi.org/10.1371/journal.pone.0136404


Predicting, Recognizing, and Treating Right Heart Failure in Patients Undergoing Durable LVAD Therapy

Despite advancements in technology, right heart failure after left ventricular assist device implantation remains a significant source of morbidity and mortality. This paper will discuss the latest evidence for diagnosis and treating post-LVAD right heart disease, right heart function, and right heart function as a result of LVAD implantation.

Source link: https://doi.org/10.3390/jcm11112984


HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non‐hospital settings in the community

Abstract The accepted use of left ventricular assist device technology as a safe alternative to heart failure management in patients with advanced heart disease, as well as the improved longevity of the LVAD-u2010supported patients on the device and the scarcity of donor hearts has significantly raised the number of LVADu2010funded patients. The likelihood of an LVAD-u2010supported patient presenting with medical emergency to a local emergency department, internal, or surgical ward of a non-u2010LVAD implanting center is on the rise. Following the introduction of the assist device technology in general, definitions, and structured approach to the assessment of the LVADu2010supported patient in the ambulance and emergency department, as well as cardiopulmonary resuscitation for LVADu2010supported patients is included in this first part of the non-u2010funded patients.

Source link: https://doi.org/10.1002/ehf2.13588


Association of Genetic Polymorphisms with Complications of Implanted LVAD Devices in Patients with Congestive Heart Failure: A Kazakhstani Study

Heart failure patients on the left ventricular assist device is one of the alternative heart failure treatments. The aim of the study was to investigate the role of single-nucleotide polymorphisms in HF patients with LVAD problems. We analyzed 21 SNPs in HF patients with/without complications, as well as healthy controls. Patients can be given warfarin and aspirin in a customized dose, and LVAD difficulties can be predicted by referring to their genotype polymorphisms in VKORC1, ITGB3, and UGT1A6 genes.

Source link: https://doi.org/10.3390/jpm12050744


Inpatient Specialist Palliative Care in Patients With Left Ventricular Assist Devices (LVAD): A Retrospective Case Series

To which extent have LVAD patients been sent sPC, how early is sPC involved? Patients accompanied their family and meant Eastern Cooperative Oncology Group's success status was three. The mean time between LVAD implantation and the first sPC contact was 1. 71 years, with a variety of first sPC contacts from 49 days before implantation to more than six years since. The time between the first sPC call and in-hospital death in Duesseldorf, Germany, was 10. 2 days. paraphrasedoutput:Conclusion: The integration of sPC in LVAD patients despite unequivocal findings demonstrating the need for sPC expertise, ethical, and communicative issues, as well as the available resources in the area, is yet to be fully developed.

Source link: https://doi.org/10.3389/fcvm.2022.879378


LVAD as a Bridge to Remission from Advanced Heart Failure: Current Data and Opportunities for Improvement

Left ventricular assist systems are a common treatment technique for advanced heart failure. For the benefit of the larger HF community, we'll explore current and future opportunities to promote LVAD-mediated reverse remodeling and enhance our pathophysiological knowledge of HF and recovery.

Source link: https://doi.org/10.3390/jcm11123542


Right heart failure before LVAD implantation predicts right heart failure after LVAD implantation – is it that easy?

Abstract Background Right heart failure after left ventricular assist device implantation is common and is associated with poor outcomes. After 3, 6 and 12 months, the prevalence of late RHF and death from RHF was elevated. Pre-existing RHF was only relevant for early RHF and dependable, but not for new onset late RHF. RHF was not measured differently by modelling three clinical studies to see comparisons of regression models' predictive value against a series of three clinical findings. RHF prior to LVAD adoption raises the risk of early RHF and persistent late RHF, but not for new onset late RHF, bolstering the assumption of differences in the etiology. New onset late RHF had no predicted value for echocardiographic or hemodynamic measurements. According to identical predictive value of clinical findings and statistical models of risk factors, a clinical evaluation is equally matched to predict RHF.

Source link: https://doi.org/10.1186/s13019-020-01150-x

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions